NCT02401048 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Status COMPLETED Phase PHASE1/PHASE2
NCT02400333 Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet Status COMPLETED Phase PHASE1
NCT02398747 Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies Status COMPLETED Phase PHASE1
NCT02398058 Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) Status COMPLETED Phase PHASE1
NCT02392676 Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations Status WITHDRAWN Phase PHASE3
NCT02388295 AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients Status COMPLETED Phase PHASE2
NCT02386917 Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers Status ACTIVE_NOT_RECRUITING Phase NA
NCT02383290 The Implementation of Pharmacogenomics Into Primary Care in British Columbia Status COMPLETED Phase NA
NCT02380521 Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes Status COMPLETED Phase PHASE4
NCT02379676 Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation Status UNKNOWN Phase PHASE4
NCT02375724 BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH Status COMPLETED Phase PHASE4
NCT02374645 A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC Status COMPLETED Phase PHASE1
NCT02372344 A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects Status COMPLETED Phase PHASE1
NCT02371187 Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? Status COMPLETED Phase PHASE2
NCT02370537 A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Status COMPLETED Phase PHASE2
NCT02369874 Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Status COMPLETED Phase PHASE3
NCT02367066 A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM) Status COMPLETED Phase PHASE1